The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Qian, Haili ^a   Gao, Feng ^b   Wang, Haijuan ^a   Ma, Fei ^a  

^a CANCER HOSPITAL   (China)

^b General Staff Department of Chinese PLA   (China)

Author keywords

Anaplastic lymphoma kinase (ALK); Crizotinib; Meta analysis; Non small cell lung cancer (NSCLC)

Indexed keywords

ALANINE AMINOTRANSFERASE; ANAPLASTIC LYMPHOMA KINASE; ASPARTATE AMINOTRANSFERASE; CRIZOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY DYSFUNCTION; META ANALYSIS; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; VISUAL DISORDER; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84912097465     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-683     Document Type: Article

References (26)

1. Weinmann M, Jeremic B, Toomes H, Friedel G, Bamberg M. Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer. Lung Cancer 2003, 39(3):233-253. 10.1016/S0169-5002(02)00454-3, 12609562.
2. Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics 2013, 7:91-101. 3643289, 23671386.
3. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29(21):2866-2874. 10.1200/JCO.2010.33.4235, 21670455.
4. Klastersky J, Paesmans M. Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer 2001, 34(Suppl 4):S95-S101.
5. American Cancer Society Cancer Facts & Figures 2013 2013, http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/, American Cancer Society.
6. Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A. Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs Today (Barc) 2012, 48(4):271-282. 10.1358/dot.2012.48.4.1769835, 22536569.
7. Kanteti R, El-Hashani E, Dhanasingh I, Tretiakova M, Husain AN, Sharma S, Sharma J, Vokes EE, Salgia R. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer 2014, 14:185. 10.1186/1471-2407-14-185, 3995599, 24628993.
8. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566. 10.1038/nature05945, 17625570.
9. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131(6):1190-1203. 10.1016/j.cell.2007.11.025, 18083107.
10. Steuer CE, Ramalingam SS. ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options. Cancer 2014, 120(16):2392-2402. 10.1002/cncr.28597, 24853389.
11. Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer 2013, 13:262. 10.1186/1471-2407-13-262, 3671182, 23714228.
12. Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anticancer Drugs 2013, 24(10):1039-1046. 10.1097/CAD.0000000000000011, 23962905.
13. Berge EM, Lu X, Maxson D, Baron AE, Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M, Camidge DR. Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer 2013, 14(6):636-643. 10.1016/j.cllc.2013.06.005, 4126227, 23931899.
14. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703. 10.1056/NEJMoa1006448, 3014291, 20979469.
15. Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013, 73(18):2031-2051. 10.1007/s40265-013-0142-z, 24288180.
16. Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol 2013, 8(1):55-67. 10.1007/s11523-012-0250-9, 23325296.
17. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999, 354(9193):1896-1900. 10.1016/S0140-6736(99)04149-5, 10584742.
18. Hunter JE, Schmidt FL. Fixed effects vs. random effects meta-analysis models: implications for cumulative research knowledge. Int J Sel Assess 2000, 8(4):275-292.
19. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13(10):1011-1019. 10.1016/S1470-2045(12)70344-3, 3936578, 22954507.
20. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12(11):1004-1012. 10.1016/S1470-2045(11)70232-7, 3328296, 21933749.
21. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, OByrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394. 10.1056/NEJMoa1214886, 23724913.
22. Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Baron AE, Chonchol M, Camidge DR. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2013, 120(5):664-674.
23. Riely GJ, Evans TL, Salgia R, Ou SI, Gettinger SN, Otterson GA, Lanzalone S, Polli A, Shaw AT. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Paper presented at: the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. 2012, Chicago, IL, Abstract 3.
24. O'Bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother 2013, 47(2):189-197. 10.1345/aph.1R002, 23386065.
25. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011, 5:471-485. 3232174, 22162641.
26. Curran MP. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 2012, 72(1):99-107. 10.2165/11207680-000000000-00000, 22191798.